This suggests that the already low MSTN levels in DMD patients may reduce the effectiveness of MSTN inhibitors, as further lowering MSTN might not significantly increase muscle mass, as discussed by Mariot et al. (2017) [95]. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.